Harnessing the power of antibodies to fight bone metastasis
暂无分享,去创建一个
X. Zhang | Yuda Chen | Zeru Tian | Lushun Wang | A. Loredo | Ling Wu | Weijie Zhang | Kuan-Lin Wu | Han Xiao | I. Bado | Hai Wang | Zhan Xu | Chenfei Yu | Igor L Bado
[1] Purba Singh,et al. The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. , 2021, Developmental cell.
[2] X. Zhang,et al. The bone microenvironment invigorates metastatic seeds for further dissemination , 2020, Cell.
[3] P. Parren,et al. Bispecific antibodies: a mechanistic review of the pipeline , 2019, Nature Reviews Drug Discovery.
[4] S. O'Reilly,et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.
[5] S. Stewart,et al. Understanding the Bone in Cancer Metastasis , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] Stephen T. C. Wong,et al. The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. , 2018, Cancer cell.
[7] L. Esserman,et al. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer , 2018, npj Breast Cancer.
[8] G. Hortobagyi,et al. Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases , 2018, The oncologist.
[9] A. Karpeisky,et al. Bisphosphonate conjugation for bone specific drug targeting , 2018, Bone reports.
[10] R. Young,et al. Targeting therapeutics to bone by conjugation with bisphosphonates , 2018, Current opinion in pharmacology.
[11] David L. Marron,et al. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer , 2018, The Journal of clinical investigation.
[12] Gustav Stålhammar,et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes , 2018, The Journal of clinical investigation.
[13] H. Sørensen,et al. Survival after bone metastasis by primary cancer type: a Danish population-based cohort study , 2017, BMJ Open.
[14] W. Mackenzie,et al. Development of Bone Targeting Drugs , 2017, International journal of molecular sciences.
[15] Stephen T. C. Wong,et al. Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies , 2017, Nature Communications.
[16] Lajos Pusztai,et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations , 2017, Nature Communications.
[17] A. Tolcher. Antibody drug conjugates: lessons from 20 years of clinical experience. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] X. Zhang,et al. Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis. , 2016, Journal of visualized experiments : JoVE.
[19] G. Adams,et al. Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance , 2016, Journal of immunotherapy.
[20] R. Roeder,et al. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. , 2016, Advanced drug delivery reviews.
[21] Xiaojuan He,et al. Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders , 2016, International journal of molecular sciences.
[22] Paul Polakis,et al. Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.
[23] Lauren E. Jansen,et al. A cell-ECM screening method to predict breast cancer metastasis. , 2015, Integrative biology : quantitative biosciences from nano to macro.
[24] Stephen T. C. Wong,et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. , 2015, Cancer cell.
[25] R. Rawal,et al. The critical role of bisphosphonates to target bone cancer metastasis: an overview , 2015, Journal of drug targeting.
[26] M. Clemons,et al. Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre , 2013, Journal of bone oncology.
[27] Brian Ell,et al. SnapShot: Bone Metastasis , 2012, Cell.
[28] F. Kratz,et al. Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix. , 2012, Journal of medicinal chemistry.
[29] A. Santoro,et al. Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. , 2012 .
[30] Dafydd G. Thomas,et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. , 2012, Cancer research.
[31] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[32] A. Boyde,et al. The relationship between the chemistry and biological activity of the bisphosphonates. , 2011, Bone.
[33] J. Forbes,et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] H. Komatsu. [Antibody therapy in cancer]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.
[36] Thomas Singer,et al. The safety and side effects of monoclonal antibodies , 2010, Nature Reviews Drug Discovery.
[37] J. Descotes. Immunotoxicity of monoclonal antibodies , 2009, mAbs.
[38] J. Chirgwin,et al. Molecular biology of bone metastasis. , 2008, Molecular cancer therapeutics.
[39] A. Giuliano,et al. Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype , 2006, Clinical Cancer Research.
[40] L. V. van de Poll-Franse,et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group , 2006, BMC Cancer.
[41] G. Hortobagyi,et al. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.
[42] T. Fehm,et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients , 2006, Breast Cancer Research and Treatment.
[43] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] H. Hirabayashi,et al. Relationship Between Physicochemical and Osteotropic Properties of Bisphosphonic Derivatives: Rational Design for Osteotropic Drug Delivery System (ODDS) , 2001, Pharmaceutical Research.
[45] H. Fleisch. Bisphosphonates in Bone Disease: From the Laboratory to the Patient , 2000 .
[46] R K Jain,et al. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. , 1995, Cancer research.
[47] R. A. Holmes,et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[48] R. Rubens,et al. The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.
[49] J. Moore,et al. Bone Metastasis , 1982, British Journal of Cancer.
[50] J. Thigpen. Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens , 2011 .
[51] P. Mahadevan,et al. An overview , 2007, Journal of Biosciences.
[52] R. Rubens,et al. Clinical course and prognostic factors following bone recurrence from breast cancer. , 1998, British Journal of Cancer.
[53] J. Bayouth,et al. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[54] M. Fanger,et al. Bispecific antibodies. , 1992, Critical reviews in immunology.